1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Parkinson Disease in 8 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay." | 1.43 | Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. ( Bähr, M; Becker, S; Dambeck, V; Eckermann, K; Fonseca-Ornelas, L; Koch, JC; Lingor, P; Lopes da Fonseca, T; Outeiro, TF; Tatenhorst, L; Tönges, L; Walle, H; Zweckstetter, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostendorf, F | 1 |
| Metzdorf, J | 1 |
| Gold, R | 1 |
| Haghikia, A | 1 |
| Tönges, L | 3 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| Labandeira-Garcia, JL | 1 |
| Muñoz, A | 1 |
| Tatenhorst, L | 2 |
| Saal, KA | 1 |
| Koch, JC | 2 |
| Szegő, ÉM | 1 |
| Bähr, M | 2 |
| Lingor, P | 2 |
| Eckermann, K | 1 |
| Dambeck, V | 1 |
| Fonseca-Ornelas, L | 1 |
| Walle, H | 1 |
| Lopes da Fonseca, T | 1 |
| Becker, S | 1 |
| Outeiro, TF | 1 |
| Zweckstetter, M | 1 |
| Li, YH | 1 |
| Yu, JW | 1 |
| Xi, JY | 1 |
| Yu, WB | 1 |
| Liu, JC | 1 |
| Wang, Q | 1 |
| Song, LJ | 1 |
| Feng, L | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Xiao, BG | 1 |
| Ma, CG | 1 |
| Nichols, RJ | 2 |
| Dzamko, N | 2 |
| Hutti, JE | 1 |
| Cantley, LC | 1 |
| Deak, M | 2 |
| Moran, J | 1 |
| Bamborough, P | 1 |
| Reith, AD | 2 |
| Alessi, DR | 2 |
| Hentati, F | 1 |
| Prescott, AR | 1 |
| Gillardon, F | 1 |
| Kremmer, E | 1 |
| Froehlich, T | 1 |
| Ueffing, M | 1 |
| Hengerer, B | 1 |
| Gloeckner, CJ | 1 |
8 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Parkinson Disease
| Article | Year |
|---|---|
Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cell Survival; Cells, Cul | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Stria | 2014 |
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Prot | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Enzyme Activation; Enzyme Inhibitors | 2009 |
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 14-3-3 Proteins; Amino Acid Sequence; Animals; Blotti | 2010 |
ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; Amino Acid Sequence; Amino Ac | 2013 |